药物发现外包市场规模、份额、成长分析、按工作流程、按治疗领域、按地区 - 行业预测，2024-2031 年

2022 年全球药物发现外包市场规模约 34 亿美元，预测期内（2024-2031 年）复合年增长率为 7.2%，高于 2023 年的 36 亿美元，预计 2022 年将达到 63 亿美元。年，预计将达到10亿美元。

由于对具有成本效益和高效的药物开发流程的需求不断增加，全球药物发现外包市场正在显着增长。製药公司正在转向外包来获取专业知识、先进技术和可扩展的资源。这种转变使公司能够专注于其核心竞争力，同时降低营运成本并加快药物发现时间表。此外，随着药物开发变得更加复杂和监管要求变得更加严格，公司越来越多地与委外研发机构(CRO) 合作，以提供创新的解决方案和全面的服务。由于大型製药公司和研究机构的存在，北美和欧洲等研究地区占据了市场主导地位。然而，市场也面临着资料隐私问题、智慧财产权问题以及外包合作伙伴提供的服务品质不一致等挑战，这可能会阻碍成长。儘管存在这些挑战，技术进步和生物技术投资的增加预计将在市场上创造新的机会。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 监管分析
• 案例研究分析

药物发现外包市场：依工作流程划分

• 市场概况
• 目标识别和筛检
• 目标检验和功能资讯学
• 潜在客户识别和候选优化
• 临床前开发
• 其他相关工作流程

药物发现外包市场：依治疗领域

• 市场概况
• 呼吸系统
• 疼痛和麻醉
• 肿瘤学
• 眼科
• 血液学
• 心血管
• 内分泌
• 胃肠道
• 免疫调节
• 抗感染
• 中枢神经系统
• 皮肤科
• 泌尿生殖系统

药物发现外包市场：按药物类型

• 市场概况
• 低分子
• 大分子（生物製药）

药物发现外包市场：依服务类型

• 市场概况
• 化学服务
• 生物服务

药物发现外包市场：依最终用户划分

• 市场概况
• 製药和生物技术公司
• 学术机构
• 其他的

药物发现外包市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Charles River Laboratories International, Inc.
• WuXi AppTec Co., Ltd.
• Laboratory Corporation of America Holdings（LabCorp）
• Evotec SE
• Covance Inc.
• Thermo Fisher Scientific Inc.
• Eurofins Scientific
• Pharmaron Beijing Co., Ltd.
• Syngene International Ltd.
• Genscript Biotech Corporation
• ChemPartner
• Jubilant Biosys Ltd.
• ICON plc
• QuintilesIMS（IQVIA）
• Cambrex Corporation
• Viva Biotech
• Domainex Ltd.
• Curia Global, Inc.（formerly Albany Molecular Research, Inc.）
• Tecan Group Ltd.
• Shanghai Medicilon Inc.

Global Drug Discovery Outsourcing Market size was valued at around 3.4 billion in 2022 and is expected to rise from USD 3.6 billion in 2023 to reach a value of USD 6.3 billion by 2031, at a CAGR of 7.2% over the forecast period (2024-2031).

The Global Drug Discovery Outsourcing Market is witnessing significant growth, driven by an increasing demand for cost-effective and efficient drug development processes. Pharmaceutical companies are increasingly leveraging outsourcing to access specialized expertise, advanced technologies, and scalable resources. This shift allows firms to focus on their core competencies while reducing operational costs and expediting the drug discovery timeline. Additionally, the rising complexity of drug development, coupled with stringent regulatory requirements, is pushing companies to collaborate with Contract Research Organizations (CROs) that offer innovative solutions and comprehensive services. Regions like North America and Europe dominate the market, owing to the presence of major pharmaceutical companies and research institutions. However, the market also faces challenges such as data privacy concerns, intellectual property issues, and the variability in the quality of services provided by outsourcing partners, which could potentially hinder growth. Despite these challenges, advancements in technology and increasing investments in biotech are expected to create new opportunities within the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery Outsourcing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Discovery Outsourcing Market Segmental Analysis

Global Drug Discovery Outsourcing Market is segmented by Workflow, Therapeutics Area, Drug Type, Service Type, End User, and region. Based on Workflow, the market is segmented into Target Identification & Screening, Target Validation & Functional Informatics, Lead Identification & Candidate Optimization, Preclinical Development, and Other Associated Workflow. Based on Therapeutics Area, the market is segmented into Respiratory system, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-infective, Central Nervous System, Dermatology, and Genitourinary System. Based on Drug Type, the market is segmented into Small Molecules, Large Molecules (Biopharmaceuticals). Based on Service Type, the market is segmented into Chemistry Services, Biology Services. Based on End User, the market is segmented into Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Drug Discovery Outsourcing Market

Technological advancements are a pivotal driver of the Global Drug Discovery Outsourcing Market. The integration of cutting-edge technologies such as artificial intelligence (AI), machine learning, and big data analytics into drug discovery processes has revolutionized the landscape. These technologies enable faster data analysis, predictive modeling, and more accurate identification of potential drug candidates. By outsourcing to firms that specialize in these advanced methodologies, pharmaceutical companies can enhance their research efficiency, reduce time-to-market, and improve the overall success rate of drug development. Furthermore, advancements in automation and high-throughput screening techniques are allowing for more efficient laboratory processes, further supporting the trend toward outsourcing. As the drug discovery process becomes increasingly reliant on these technologies, the demand for specialized outsourcing services is expected to rise, driving market growth.

Restraints in the Global Drug Discovery Outsourcing Market

Data security concerns represent a significant restraint on the Global Drug Discovery Outsourcing Market. As pharmaceutical companies share sensitive research data and proprietary information with outsourcing partners, the risk of data breaches and unauthorized access becomes a pressing issue. Regulatory compliance requirements, such as the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR), impose stringent guidelines on data management and protection, complicating outsourcing arrangements. Any breach of confidentiality can lead to significant financial losses, legal repercussions, and reputational damage for pharmaceutical companies. Moreover, varying data protection laws across different countries add to the complexity, making it challenging for firms to ensure compliance. Consequently, companies may hesitate to fully embrace outsourcing, which can limit the market's growth potential.

Market Trends of the Global Drug Discovery Outsourcing Market

The increasing focus on personalized medicine is a notable trend shaping the Global Drug Discovery Outsourcing Market. As the healthcare industry shifts toward tailored treatments based on individual genetic profiles and specific patient needs, drug discovery processes must adapt accordingly. Outsourcing partners are increasingly required to develop innovative methodologies and technologies that facilitate the discovery of targeted therapies. This trend not only enhances the efficacy of drug development but also improves patient outcomes by ensuring that treatments are aligned with unique biological characteristics. The rise of biomarker research, genomic studies, and advanced analytics is driving collaboration between pharmaceutical companies and CROs, who are equipped to handle the complexities associated with personalized medicine. As this trend continues to gain momentum, the demand for specialized outsourcing services that can support the development of personalized therapies is expected to grow, influencing the overall dynamics of the market.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Regulatory Analysis
• Case Study Analysis

Drug Discovery Outsourcing Market, By Workflow

• Market Overview
• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Other Associated Workflow

Drug Discovery Outsourcing Market, By Therapeutics Area

• Market Overview
• Respiratory system
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System

Drug Discovery Outsourcing Market, By Drug Type

• Market Overview
• Small Molecules
• Large Molecules (Biopharmaceuticals)

Drug Discovery Outsourcing Market, By Service Type

• Market Overview
• Chemistry Services
• Biology Services

Drug Discovery Outsourcing Market, By End User

• Market Overview
• Pharmaceutical & Biotechnology companies
• Academic Institutes
• Others

Drug Discovery Outsourcing Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings (LabCorp)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Covance Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron Beijing Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ChemPartner
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Biosys Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuintilesIMS (IQVIA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cambrex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viva Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Domainex Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (formerly Albany Molecular Research, Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tecan Group Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Medicilon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments